Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- William J. Gradishar, MD
Robert H. Lurie Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University Medical Center
Stanford, California, United States
- Monroe Medical Associates
Chicago, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
- Albert Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 1998
- Primary completion
- 30 Sept 2004
- Completion
- 30 Jun 2005
- Last update posted
- 6 Jun 2012
- Registered enrollment
- —
- Registry id
- NCT00004175
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.